# Chemical Angel Network

> Chemical Angel Network is a VC fund backing Biotechnology and Health Care. See 8 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Houston, United States
- Total investments: 8
- Last investment: Oct 2025
- Lead investor: 0%
- Last updated: Aug 2026
- Website: http://www.chemicalangels.com

Chemical Angel Network is a VC fund in Houston focused on Biotechnology and Health Care. The Chemical Angel Network provides a mechanism for accredited angel investors to source and vet quality early-stage investment opportunities, assist entrepreneurs and early-stage growth companies and be a quality source for information, educational resources and advisors. A key aim for these investments will be economic development within theChemical Industry by helping emerging companies grow to profitability and/or grow to Venture Capital scale investments. The Chemical Angel Network measures its success by the quality of deal flow, amount of dollars invested, number of companies funded and most importantly ROI for members.

## Contacts

5 contacts available for Chemical Angel Network. Shizune tracks 1 team members at Chemical Angel Network. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/chemical-angel-network?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 63% |
| Health Care | 4 | 50% |
| Therapeutics | 2 | 25% |
| Manufacturing | 2 | 25% |
| Chemical | 1 | 13% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 5 | 63% |
| Series A | 2 | 25% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| William D. Provine | Member | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Phosio Corporation | Phosio Corporation develops a photoresist material for the fabrication of high aspect ratio nanostructures. The company was founded in 2018 as a spin-off from Oregon State University's Department of Chemistry and the NSF-funded Center for Sustainable Materials Chemistry. | $300K | Seed | Oct 01, 2025 |  |
| Axio BioPharma | Axio BioPharma is building the vendor-neutral data infrastructure for biomanufacturing.Biomanufacturing runs on a dozen enterprise systems that do not talk to each other. LIMS, MES, ELN, Historian, ERP, QMS, and more. Every tech transfer, every investigation, and every handoff between pharma sponsors and their manufacturing partners breaks on thesame problem: critical process data is fragmented across organizational and technical boundaries.We are not building AI models. We are building the coordination layer that makes AI possible.Axio Lattice is a federated data platform that connects process data across sponsors and their manufacturing partners without centralizing it. Data stays in pharma's environment. Ownership never changes hands. Meaning is standardized through a neutral layer that works across every major enterprise system biomanufacturing depends on.Axio Lab is a Madison-based, non-GMP, high-throughput antibody production facility. It delivers fee-for-service campaigns to biotech and pharma teams while generating the clean, structured datasets and commercial relationships that seed Lattice deployments.We are vendor-neutral by design. Large manufacturers cannot host this network because sponsors will not put their process data on a competitor's platform. Pharma-built internal data teams cannot solve it alone because the problem is cross-organizational by definition. Axio sits between them, owned by neither, trusted by both.Headquartered in Madison, Wisconsin. Backed by operators and advisors from Catalent, CrowdStrike, Danaher, and the Allen Institute.If you are a sponsor, manufacturing partner, or technology vendor working on the data fragmentation problem, we would like to hear from you. | $1.3M | Seed | Jan 01, 2025 |  |
| RealSeq Biosciences | RealSeq Biosciences’ core expertise includes innovative proprietary technologies for bias-free small RNA/miRNA NGS library construction. | $1.5M | Seed | Jul 28, 2023 |  |
| CARI Health | Cari Health develops remote medication monitors that allow clinicians to prescribe medications and receive real-time reporting on medication levels. Its monitors are wireless sensors that are worn on the patient's skin and continuously send data about medication levels to the cloud.The company was founded in 2015, incorporated in 2021 and isheadquartered in San Diego, California. | $2.3M | Seed | Jan 10, 2023 |  |
| Amplified Sciences | Amplified Sciences is a molecular diagnostics company unlike other diagnostics companies due to their ultra-sensitive molecular sensing technology with composition of matter IP exclusively licensed from Purdue University. The technology is disease state agnostic, can detect to the single molecule level, scales easily to point of care, and providesa very favorable cost structure for their platform of reagents. The first application – early detection of pancreatic cancer - is an assay that will quickly prove the investment thesis due to large unmet medical need and a favorable reimbursement path. The team has delivered a working prototype and published proof of concept data. | $1.8M | Seed | Aug 25, 2021 |  |
| Intrommune Therapeutics | Intrommune is developing the revolutionary oral mucosal immunotherapy (OMIT) treatment platform for food allergies. OMIT is a long-term, patient-friendly, disease-modifying solution for the 220 million people, including 9 million adults and 6 million children in the U.S., who suffer from life-altering food allergies. Intrommune’s lead product,INT-301, is expected to be a safe, effective and convenient therapy for patients who suffer from peanut allergy. There is no FDA-approved treatment for peanut allergy or any other food allergy. | $6M | Series A | Jun 01, 2021 |  |
| Zylö Therapeutics | Zylö Therapeutics offers an innovative sustained-release drug-delivery system that was developed by Joel Friedman MD PhD, Adam Friedman MD FAAD, and Andrew Draganski PhD. The delivery system uses patented hydrogel-derived nanoparticles, called Nanopods, to deliver—in a sustained and controlled manner—notoriously hard-to-deliver therapeutic agentsthrough topical administration.The company was founded in 2017 and is based in Greenville, South Carolina. | $4M | Series A | Sep 26, 2019 |  |
| Zylö Therapeutics | Zylö Therapeutics offers an innovative sustained-release drug-delivery system that was developed by Joel Friedman MD PhD, Adam Friedman MD FAAD, and Andrew Draganski PhD. The delivery system uses patented hydrogel-derived nanoparticles, called Nanopods, to deliver—in a sustained and controlled manner—notoriously hard-to-deliver therapeutic agentsthrough topical administration.The company was founded in 2017 and is based in Greenville, South Carolina. | $4M | Series A | Sep 26, 2019 |  |

8 of 8 investments shown.

## Co-investors
- Ariel Southeast Angel Partners — VC Fund, 2 deals together
- [Boston Harbor Angels](https://shizune.co/investors/profile/boston-harbor-angels) — VC Fund, 2 deals together
- [New York Angels](https://shizune.co/investors/profile/new-york-angels) — VC Fund, 2 deals together
- SC Launch, Inc. — VC Fund, 2 deals together
- [VentureSouth](https://shizune.co/investors/profile/south-carolina-angel-network) — VC Fund, 2 deals together
- [Angel Star Ventures](https://shizune.co/investors/profile/angel-star-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Chemical Angel Network invest in?

Chemical Angel Network invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Seed and Series A stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Chemical Angel Network?

Public channels for Chemical Angel Network include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Chemical Angel Network?

The team at Chemical Angel Network includes William D. Provine (Member). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co